A Nomogram Associated with High Probability of Malignant Nodes in the Surgical Specimen After Trimodality Therapy of Patients with Oesophageal Cancer
Overview
Authors
Affiliations
Background: The presence of malignant lymph nodes (+ypNodes) in the surgical specimen after preoperative chemoradiation (trimodality) in patients with oesophageal cancer (EC) portends a poor prognosis for overall survival (OS) and disease-free survival (DFS). Currently, none of the clinical variables highly correlates with +ypNodes. We hypothesised that a combination of clinical variables could generate a model that associates with high likelihood of +ypNodes after trimodality in EC patients.
Methods: We report on 293 consecutive EC patients who received trimodality therapy. A multivariate logistic regression analysis that included pretreatment and post-chemoradiation variables identified independent variables that were used to construct a nomogram for +ypNodes after trimodality in EC patients.
Results: Of 293 patients, 91 (31.1%) had +ypNodes. OS (p=0.0002) and DFS (p<0.0001) were shorter in patients with +ypNodes compared to those with -ypNodes. In multivariable analysis, the significant variables for +ypNodes were: baseline T-stage (odds ratio [OR], 7.145; 95% confidence interval [CI], 1.381-36.969; p=0.019), baseline N-stage (OR, 2.246; 95% CI, 1.024-4.926; p=0.044), tumour length (OR, 1.178; 95% CI, 1.024-1.357; p=0.022), induction chemotherapy (OR, 0.471; 95% CI, 0.242-0.915; p=0.026), nodal uptake on post-chemoradiation positron emission tomography (OR, 2.923; 95% CI, 1.007-8.485; p=0.049) and enlarged node(s) on post-chemoradiation computerised tomography (OR, 3.465; 95% CI, 1.549-7.753; p=0.002). The nomogram after internal validation using the bootstrap method (200 runs) yielded a high concordance index of 0.756.
Conclusion: Our nomogram highly correlates with the presence of +ypNodes after chemoradiation, however, considerably more refinement is needed before it can be implemented in the clinic.
Development of a Nomogram to Predict the Outcome for Patients with Soft Tissue Sarcoma.
Bray J, Munday J Vet Sci. 2023; 10(4).
PMID: 37104421 PMC: 10146366. DOI: 10.3390/vetsci10040266.
Qiao B, Zhao M, Wu J, Wu H, Zhao Y, Meng F Biomed Res Int. 2020; 2020:4252580.
PMID: 32934959 PMC: 7479460. DOI: 10.1155/2020/4252580.
Wang G, Chang Y, Wu X, Li X, Li L, Zhang M Oncol Lett. 2019; 18(4):3493-3500.
PMID: 31516567 PMC: 6732941. DOI: 10.3892/ol.2019.10719.
Qu A, Yang Y, Zhang X, Wang W, Liu Y, Zheng G EBioMedicine. 2018; 37:125-133.
PMID: 30314890 PMC: 6284350. DOI: 10.1016/j.ebiom.2018.09.052.
Goense L, Ruurda J, Carter B, Fang P, Ho L, Meijer G Eur J Nucl Med Mol Imaging. 2018; 45(10):1742-1751.
PMID: 29663014 PMC: 6097755. DOI: 10.1007/s00259-018-4011-6.